Gabapentin’s anxiolytic and sedative properties along with its overall safety profile suggest that it may be a viable adjuvant to lorazepam in the management of acute alcohol withdrawal. By Christopher Wilming, Mariah Alford, and Lynnette Klaus On average, the required benzodiazepine dosage was lower with concomitant use of gabapentin in [...]
In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis products not only in its home country but also in Europe. Nanaimo, British Columbia-based Tilray announced today that it has a binding [...]
The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10 to 17 years. Lurasidone, a serotonin dopamine antagonist, is already approved in the [...]
In a fascinating note in today's Journal of the American Medical Association (JAMA), Robert M. Post of the George Washington University School of Medicine attributes stigma as one of the main factors contributing to inadequate recognition and treatment of recurrent mood disorders, including unipolar depression and bipolar disorder. "This Viewpoint describes an [...]
Top 5 Articles of February 2018 Updated for 2018 Dosing and Monitoring: Child and Adolescent Psychotropic Criteria For Children And Adolescents Psychotropic Drugs: Side Effects And Teratogenic Risks Recommended Clinical Monitoring Of Children And Adolescents For Psychotropic Drugs Internet Resources READ MORE A Pilot Evaluating Clinical Pharmacy Services in an [...]
The increase in risk for alcohol use disorder (AUD) in a married individual following a diagnosis of alcoholism in the other spouse is "large and rapid," according to researchers writing recently in JAMA. The causes of this association remain unclear. Population-wide Swedish registries were used to identify individuals born in [...]
By JoAnn E. Manson, and Shari S. Bassuk Dietary supplementation is approximately a $30 billion industry in the United States, with more than 90 000 products on the market. In recent national surveys, 52% of US adults reported use of at least 1 supplement product, and 10% reported use of at least 4 such [...]
According to an evidence-based review in the journal Current Psychiatry, the answer is a qualified "Maybe." Chronic methamphetamine use can induce pathological brain changes in the brain. Users can develop thought, mood, and behavioral disorders, including psychosis. Such effects may persist even after extended abstinence. Because cognitive deficits can affect [...]
By Robin Stevenson, and Donald E. Moore Jr. Medical education is a continuum of 3 parts; undergraduate medical school education, postgraduate training, and continuing medical education (CME). CME differs from the other 2 educational components in that it has generally not been based on an explicit curriculum. Recently, CME has increasingly focused on addressing professional [...]
Eli Lilly had hoped that EXPEDITION3 would prove to the world that amyloid beta was the cause of Alzheimer’s and that solanezumab could bend the curve of cognitive decline back to patients’ favor — or at least for patients with an early-stage, mild form of the disease. Instead, the landmark failure [...]